Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New pill could help shed pounds without surgery

NCT ID NCT07274137

Disease control Sponsor: MindRank AI Ltd Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests an experimental oral drug called MDR-001 to help adults with overweight or obesity lose weight over 52 weeks. About 738 participants will receive either the drug or a placebo, along with lifestyle advice. The main goal is to see if the drug leads to meaningful weight loss compared to placebo.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

About 738 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Feb 2026

An estimate. Start dates often move.

Expected to finish

Jul 2027

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 65 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Have given written informed consent to participate in this study * Chinese male or female participants who are aged 18-65 (inclusive) years at the time of signing the ICF * Participants who are obesity (BMI ≥ 28.0 kg/m2), or overweight (24.0 kg/m2 ≤ BMI \< 28.0 kg/m2) with at least one of the the following weight-related comorbidities at screening:1) Pre-diabetes. 2) Hypertension.3) Dyslipidemia.4) Fatty liver.5) Obstructive sleep apnea syndrome.6) Complaint of weight-bearing joint pain. * Participants had a stable weight maintenance during the 3 months of dietary and physical activity prior to screening (participant-reported data acceptable) and no more than 5% weight fluctuation Exclusion Criteria: * Obesity induced by secondary diseases or drug * Have diabetes mellitus * Have any lifetime history of a suicidal attempt or suicidal behavior * Have a history of depressive disorder * History of gout within 6 months prior to screening * History of major cardiovascular or cerebrovascular disease within 6 months prior to screening, defined as:1)Acute myocardial infarction (MI), percutaneous coronary intervention (PCI) or coronary artery bypass grafting (CABG), heart valve repair/replacement, unstable angina, hemorrhagic stroke (stroke), ischemic stroke (including transient ischemic attack \[TIA\]).2)Congestive heart failure of New York Heart Association (NYHA) class III or IV.3)Severe arrhythmias * History of malignancy within 5 years prior to screening or newly diagnosed malignancy at screening * Have a family or personal history (parents, children, and siblings of medullary thyroid cancer or Multiple Endocrine Neoplasia Syndrome Type 2 . * Abnormal thyroid function tests at screening not adequately controlled by stable medication doses , or thyroid ultrasound at screening showing thyroid nodules classified as Chinese-thyroid imaging-reporting and data system category 4 or higher. * History of significant gastrointestinal disease or gastrointestinal surgery or clinically significant gastric emptying abnormality within 6 months prior to screening. * History of intestinal disorders deemed clinically significant by the investigator, or acute hemorrhoidal episode within 3 months prior to screening. * History of acute or chronic pancreatitis, or abnormally elevated serum amylase or lipase levels at screening. * revious acute or chronic hepatitis, or symptoms and signs of any other liver disease other than non-alcoholic fatty liver disease, or abnormalities in related laboratory tests at screening * Presence of acute or chronic cholecystitis at screening, or symptomatic or treatment-requiring cholelithiasis/gallbladder polyps at screening, or newly diagnosed cholelithiasis within 6 months before screening * Hypersensitivity or suspected hypersensitivity to glucagon-like peptide 1 receptor agonist (GLP-1RA) drugs or excipients. * History of drug abuse or dependence prior to screening. * Have current or history of treatment with medications that may cause significant weight gain within 3 months prior to screening, including but not limited to: 1. Approved/unapproved marketed weight-loss drugs: orlistat, sibutramine hydrochloride, phentermine, phentermine-topiramate, naltrexone-amfebutamone, tirzepatide, semaglutide, liraglutide, beinaglutide, phendimetrazine, methylamphetamine, etc. 2. Investigational products of weight-loss: Glucagon-like peptide 1 receptor (GLP-1R) agonists, GLP-1R/glucagon receptor (GCGR) agonists, glucose-dependent insulinotropic polypeptide receptor (GIPR)/GLP-1R agonists, GIPR/GLP-1R/GCGR agonists,GLP-1R agonists/activin type II receptor (ActRII) inhibitors, GLP-1R/GIPR/fibroblast growth factor 21 receptor (FGF21R) agonists or FGF21R/GCGR/GLP-1R agonists. 3. Hypoglycemic drugs, such as metformin, sodium-glucose cotransporter 2 (SGLT2) inhibitors, thiazolidinediones (TZDs) or dipeptidyl peptidase 4 (DPP-4) inhibitors. 4. Systemic steroid therapy (including intravenous, oral, intra-articular). 5. Tricyclic antidepressants or other antipsychotic or antiepileptic drugs affecting body weight (e.g., mirtazapine, paroxetine, clozapine, olanzapine, risperidone, quetiapine, paliperidone, valproic acid, valproic acid derivatives, lithium). * History of bariatric surgery (excluding acupuncture/cupping/catgut embedding for bariatric surgery, liposuction, and abdominoplasty performed \>1 year prior to screening) or plans to undergo bariatric surgery or acupuncture/cupping/catgut embedding, liposuction, abdominoplasty during the study period. * Planned chronic use of medications affecting gastrointestinal motility or scheduled gastric emptying-impairing surgery during the study period. * Major or medium-sized surgery, or severe trauma or serious infection within 3 months prior to screening, which, as assessed by the investigator, would preclude trial participation, or planned surgery during the study period (excluding outpatient procedures deemed by the investigator to have no impact on subject safety or trial outcomes). * History of organ transplant. * Use of any drug or food known to potently or moderately inhibit or induce cytochrome P450 3A4 enzyme (CYP3A4) and/or inhibit P-glycoprotein (P-gp) within 28 days prior to the first dose and throughout the study. * Currently participating in any other clinical study, or if received any investigational product or medical devices within ≤ 3 months or 5 half-lives (t1/2) prior to screening, whichever is longer. * Donation or loss of ≥ 400 mL of blood or transfusion/blood products during this period within 3 months prior to screening, or intention to donate blood during the study. * emale participants during pregnancy or lactation. * The investigator, site personnel, and/or their immediate family members directly related to the study. An immediate family member is defined as a spouse, parent, child, or sibling, whether biological or legally adopted. * Participants who may be unable to complete this study for other reasons, or have other conditions that, as assessed by the investigator, will make the participant unsuitable for participation in this study, for example, the participant refuses to use only the weight-loss drugs specified in the protocol during the study.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Overweight or obesity are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Obesity obesity disorder Overweight

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Overweight or obesity

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    45 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Central Hospital Affiliated To Shangdong First Medical University

    Jinan, China

  • Central Hospital of Jin zhou

    Jinzhou, China

  • Dongyang People's Hospital

    Dongyang, China

  • First Hospital of Shanxi Medical University

    Taiyuan, China

  • Ganzhou People's Hospital

    Ganzhou, China

  • Huizhou Central People's Hospital

    Huizhou, China

  • Huizhou Third People's Hospital

    Huizhou, China

  • Huzhou Central Hospital

    Huzhou, China

  • Jingzhou Hospital Affiliated to Yangtze University

    Jinzhou, China

  • JiuJiang No.1 people's Hospital

    Jiujiang, China

  • Lianyungang Hospital of TCM

    Lianyungang, China

  • Liaocheng People's Hospital

    Liaocheng, China

  • Loudi Central Hospital

    Loudi, China

  • PKUCare Luzhong Hospital

    Zibo, China

  • Peking University People's Hospital

    Beijing, China

  • People's Hospital of Hunan Province

    Changsha, China

  • Pingxiang People's Hospital

    Pingxiang, China

  • Sanya Central Hospital (Hainan Third People's Hospital)

    Sanya, China

  • Shanxi Bethune Hospital

    Taiyuan, China

  • Shenyang Fifth People Hospital

    Shenyang, China

  • Shenyang Sixth People's Hospital

    Shenyang, China

  • Siping Central People's Hospital

    Siping, China

  • Taizhou Hospital of Zhejiang province

    Taizhou, China

  • The First Affiliated Hospital of Ningbo University

    Ningbo, China

  • The First Affiliated Hospital of Soochow University

    Suzhou, China

  • The First People's Hospital of Changde City

    Changde, China

  • The Fourth Hospital of Changsha

    Changsha, China

  • The People's Hospital of liaoning Province

    Shenyang, China

  • The Second Affiliated Hospital of ZhengzhouUniversity

    Zhengzhou, China

  • The Second Hospital of Anhui Medical University

    Hefei, China

  • The Second Hospital of Hebei Medical University

    Shijia Zhuang, China

  • The Second Hospital of Jilin University

    Changchun, China

  • The SecondPeople's Hospital of Hefei

    Hefei, China

  • The Third Affiliated Hospital of Jinzhou Medical University

    Jinzhou, China

  • The Third People's Hospital of Datong

    Datong, China

  • The Third People's Hospital of Zhengzhou

    Zhengzhou, China

  • Wuhan Third Hospital•Tongren Hospital of Wuhan University

    Wuhan, China

  • Xiangya Hospital Zhuzhou Central South University

    Zhuzhou, China

  • Xuancheng People's Hospital

    Xuancheng, China

  • Yichang Central People's Hospital

    Yibin, China

  • Yichang Central People's Hospital

    Yichang, China

  • Yueyang Central Hospital

    Yueyang, China

  • Yueyang People's Hospital

    Yueyang, China

  • Zibo Central Hospital

    Zibo, China

  • Zibo Municipal Hospital

    Zibo, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.